Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
December 2015
-
Media Release
Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes… -
Media Release
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on… -
Media Release
Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met… -
Media Release
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute… -
Media Release
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019… -
Media Release
Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
Data suggest myelofibrosis (MF) patients treated with Jakavi® (ruxolitinib) after 5 years lived longer despite crossover from best available therapy after week 48[1] Phase III results show… -
Media Release
Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients
More than 50 abstracts will be presented, including data on Afinitor® and investigational compounds for advanced breast cancer, showing pipeline strength Presentations highlight results of…
November 2015
-
Media Release
Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
Pivotal overall survival data for investigational compound PKC412 (midostaurin) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia Presentations highlight new CTL019 data in… -
Media Release
Novartis' heart failure medicine Entresto(TM) receives EU approval
Decision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the… -
Media Release
Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
Cosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and… -
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney's Office for the Southern District of New York
Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will… -
Media Release
Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…